<DOC>
	<DOCNO>NCT01233232</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability AZD5069 patient Chronic Obstructive Pulmonary Disease</brief_summary>
	<brief_title>A 4 Week Study Investigate Safety Tolerability AZD5069 Patients With Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<criteria>Clinical diagnosis COPD symptoms one year screen Body mass index 1830 kg/m2 weight 50100kg Current exsmokers smoke history least 10 pack year ( 1 pack year = tobacco consumption correspond 20 cigarette smoke per day one year ) screening FEV1 30 % le 80 % predict normal value postbronchodilator screen FEV1/FVC le 70 % postbronchodilator screen Any clinically significant disease disorder Exacerbation COPD resolve within 30 day first dose Patients receive live liveattenuated vaccine 2 week prior first dose Asthma current respiratory tract disorder COPD consider clinically significant Disease history suggest reduce abnormal immune function relate COPD</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease , Neutrophil , Respiratory Disease</keyword>
</DOC>